<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7435512\results\search\disease\results.xml">
  <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="need to identify effective treatments against the virus causing this" exact="disease" post="(SARSâ€�CoVâ€�2). The first clinical trials have been testing repurposed"/>
  <result pre="under way, the actual number of tested compounds is still" exact="limited" post="to approximately 20, alone or in combination. In addition,"/>
  <result pre="SARSâ€�CoVâ€�2 is a major threat to public health in the" exact="absence of" post="drugs and vaccines. The development of antiviral agents is"/>
  <result pre="exonuclease FDA Food and Drug Administration HCQ hydroxychloroquine HIV human" exact="immunodeficiency" post="virus IFN interferon IL interleukin M membrane protein mAbs"/>
  <result pre="interleukin M membrane protein mAbs monoclonal Abs MERS Middle East" exact="respiratory" post="syndrome MoA mode of action N nucleoprotein nsp nonstructural"/>
  <result pre="M membrane protein mAbs monoclonal Abs MERS Middle East respiratory" exact="syndrome" post="MoA mode of action N nucleoprotein nsp nonstructural protein"/>
  <result pre="papainâ€�like RdRp RNAâ€�dependent RNA polymerase S spike protein SARS severe" exact="acute" post="respiratory syndrome TMPRSS2 transmembrane protease serine 2 1 INTRODUCTION"/>
  <result pre="RdRp RNAâ€�dependent RNA polymerase S spike protein SARS severe acute" exact="respiratory" post="syndrome TMPRSS2 transmembrane protease serine 2 1 INTRODUCTION TO"/>
  <result pre="RNAâ€�dependent RNA polymerase S spike protein SARS severe acute respiratory" exact="syndrome" post="TMPRSS2 transmembrane protease serine 2 1 INTRODUCTION TO SARSâ€�CORONAVIRUS"/>
  <result pre="Over the last 20â€‰years, three coronaviruses (CoVs) that cause severe" exact="pulmonary" post="infections in humans have crossed the species barrier.1, 2"/>
  <result pre="the last 20â€‰years, three coronaviruses (CoVs) that cause severe pulmonary" exact="infections" post="in humans have crossed the species barrier.1, 2 The"/>
  <result pre="major public health threat.3 In approximately 20% of patients, the" exact="disease" post="progresses to severe pneumonia, respiratory and multiâ€�visceral failure, often"/>
  <result pre="approximately 20% of patients, the disease progresses to severe pneumonia," exact="respiratory" post="and multiâ€�visceral failure, often leading to death of patients"/>
  <result pre="and effective antiviral therapies are urgently needed, due to the" exact="absence of" post="a vaccine. Coronaviruses belong to the Nidovirales order, a"/>
  <result pre="described in Figure 1, begins by the attachment of the" exact="viral" post="particle to the angiotensinâ€�converting enzyme 2 (ACE2) cell surface"/>
  <result pre="achieved by endocytosis and/or direct fusion of the cell and" exact="viral" post="membranes. This step requires S protein activation. The S"/>
  <result pre="synthesized as an inactive precursor that is inserted in the" exact="viral" post="membrane, and requires two subsequent cleavages by cellular proteases"/>
  <result pre="a second proteolytic cleavage is required at the S2â€² site" exact="localized" post="immediately upstream of the fusion peptide,12, 13 and seems"/>
  <result pre="peptide,12, 13 and seems to involve at least TMPRSS2.14 The" exact="viral" post="genome is then released into the cytoplasm of the"/>
  <result pre="of the infected cells. This allows the translation of the" exact="viral" post="mRNA into two polyprotein precursors, pp1a and pp1ab, controlled"/>
  <result pre="ribosomal frameshift. These polyprotein precursors are then cleaved by two" exact="viral" post="proteases, chymotrypsinâ€�like 3 (3CLpro) and papainâ€�like (PLpro), to generate"/>
  <result pre="replication, mRNA synthesis and capping. At the final stage of" exact="viral infection," post="the N protein assembles with the neoâ€�synthesized viral genome"/>
  <result pre="of viral infection, the N protein assembles with the neoâ€�synthesized" exact="viral" post="genome to form the nucleocapsid that associates with the"/>
  <result pre="viral genome to form the nucleocapsid that associates with the" exact="viral" post="structural proteins to generate new virions released by exocytosis.6"/>
  <result pre="mainly based on existing drugs that were developed to treat" exact="viral infection" post="or other diseases. Moreover, the many different clinical trials"/>
  <result pre="based on existing drugs that were developed to treat viral" exact="infection" post="or other diseases. Moreover, the many different clinical trials"/>
  <result pre="trials currently in progress (more than 2400) are testing a" exact="limited" post="set of drugs, alone or in combination.15 Although the"/>
  <result pre="the other hand, the emergence of SARSâ€�CoV and Middle East" exact="respiratory" post="syndrome coronavirus (MERSâ€�CoV) has led to a growing number"/>
  <result pre="other hand, the emergence of SARSâ€�CoV and Middle East respiratory" exact="syndrome" post="coronavirus (MERSâ€�CoV) has led to a growing number of"/>
  <result pre="important for Covidâ€�19 management. 2 CLASSICAL ANTIVIRAL APPROACHES In the" exact="absence of" post="specific therapeutics, supportive care (eg, oxygen therapy or mechanical"/>
  <result pre="severe Covidâ€�19 symptoms.16 To limit virus proliferation in the early" exact="disease" post="stages and reduce its severity, one important strategy is"/>
  <result pre="ACE2 receptors, (b) enzymes that catalyze S protein cleavage, (c)" exact="viral" post="entry, (d) polyprotein processing, and (e) replication/transcription complex. These"/>
  <result pre="now assessed in small animal models and/or clinical trials. 2.1" exact="Antibody" post="neutralization A useful therapeutic strategy consists in interfering with"/>
  <result pre="strategy consists in interfering with the first step of the" exact="viral" post="cycle by targeting the interaction of the viral S"/>
  <result pre="of the viral cycle by targeting the interaction of the" exact="viral" post="S protein with the cell surface receptors. It was"/>
  <result pre="with Covidâ€�19 contain neutralizing antibodies (Abs) that can limit SARSâ€�CoVâ€�2" exact="viral infection" post="inâ€‰vitro.17 Moreover, administration of plasma from convalescent patients has"/>
  <result pre="Covidâ€�19 contain neutralizing antibodies (Abs) that can limit SARSâ€�CoVâ€�2 viral" exact="infection" post="inâ€‰vitro.17 Moreover, administration of plasma from convalescent patients has"/>
  <result pre="from convalescent patients has shown some efficacy in patients with" exact="respiratory" post="distress, suggesting that passive immunity might help limit SARSâ€�CoVâ€�2"/>
  <result pre="plasma therapy.23 The development of monoclonal Abs (mAbs) against the" exact="viral" post="S protein is also an option.24 This approach was"/>
  <result pre="mAbs against ACE2 is also an interesting option to reduce" exact="viral" post="entry,32, 33 but could be more risky due to"/>
  <result pre="entry into the cell.34 This strategy seems to limit SARSâ€�CoVâ€�2" exact="infection" post="in cell culture, but the stability of the soluble"/>
  <result pre="against other cellular receptors, such as CD147, also can block" exact="viral infection" post="in cell culture, and the direct interaction between CD147"/>
  <result pre="other cellular receptors, such as CD147, also can block viral" exact="infection" post="in cell culture, and the direct interaction between CD147"/>
  <result pre="viruses63 and stimulating the immune response.38 Moreover, umifenovir inhibits SARSâ€�CoVâ€�2" exact="infection" post="in vitro with an IC50 of 10 Î¼M.39 Although"/>
  <result pre="small group of patients showed a significant decrease of the" exact="viral" post="load in the arm treated with umifenovir in combination"/>
  <result pre="TABLE 1 Main antiviral molecules currently being tested against SARSâ€�CoVâ€�2" exact="infection" post="Compounds Target/MoA Tests in vitro (CoV) Clinical trials SARSâ€�CoVâ€�2"/>
  <result pre="pp1a and pp1ab are processed into 16 nsps by the" exact="viral" post="proteases 3CLpro and PLpro. These cleavage events play a"/>
  <result pre="among others, of the RNAâ€�dependent RNA polymerase (RdRp) required for" exact="viral" post="RNA replication and transcription. Due to the high conservation"/>
  <result pre="was optimized and showed antiviral activity against SARSâ€�CoVâ€�2 at concentrations" exact="lower" post="than 10 Î¼M in Calu3 lung cells. Protease inhibitors"/>
  <result pre="Î¼M in Calu3 lung cells. Protease inhibitors used in human" exact="immunodeficiency" post="virus (HIV) therapy, such as lopinavir/ritonavir (a combination known"/>
  <result pre="exclusive mechanisms. First, incorporation of nucleotide analogs (NAs) in the" exact="viral" post="RNA by the errorâ€�prone polymerase can induce early chain"/>
  <result pre="an obligate (immediate) or nonobligate fashion, resulting in incomplete, noninfectious" exact="viral" post="RNA. The second mechanism, named error catastrophe, is associated"/>
  <result pre="associated with the insertion and extension of NAs throughout the" exact="viral" post="RNA that result in many errors during RNA synthesis.65,"/>
  <result pre="analogs have been successfully used for the treatment of other" exact="viral" post="diseases, the situation is complicated in CoVs due to"/>
  <result pre="is complicated in CoVs due to the presence of a" exact="viral" post="exonuclease (nsp14 ExoN) with proofâ€�reading activity that can reduce"/>
  <result pre="not randomized and furthermore did not report the change in" exact="viral" post="load following treatment.50 While some adverse effects were reported,"/>
  <result pre="the micromolar range (0.09â€�0.3 Î¼M), without apparent interference from the" exact="viral" post="proofreading activity of nsp14.52 In infected cells, decreased viral"/>
  <result pre="the viral proofreading activity of nsp14.52 In infected cells, decreased" exact="viral" post="replication was associated with increased mutation frequency, supporting a"/>
  <result pre="of lethal mutagenesis. Moreover, the orally bioavailable Î²â€�Dâ€�N4â€�hydroxycytidineâ€�5â€²â€�isopropyl ester improved" exact="pulmonary" post="function and reduced virus titer and body weight loss"/>
  <result pre="several clinical trials.42, 51 The preliminary results suggest a faster" exact="viral" post="clearance time in the favipiravir arm compared with the"/>
  <result pre="active against SARSâ€�CoVâ€�2 is sofosbuvir, a broadâ€�acting antiviral approved for" exact="hepatitis C" post="virus infection management. A recent study showed that sofosbuvir"/>
  <result pre="SARSâ€�CoVâ€�2 is sofosbuvir, a broadâ€�acting antiviral approved for hepatitis C" exact="virus infection" post="management. A recent study showed that sofosbuvir triphosphate is"/>
  <result pre="is sofosbuvir, a broadâ€�acting antiviral approved for hepatitis C virus" exact="infection" post="management. A recent study showed that sofosbuvir triphosphate is"/>
  <result pre="treatment in patients with Covidâ€�19 are unknown, due to the" exact="absence of" post="largeâ€�scale clinical studies. Moreover, it is important to consider"/>
  <result pre="consider the risk of overdose and of unexpected increase of" exact="viral" post="load or symptoms. Several teams have already set up"/>
  <result pre="interferon (IFN) could be used during the early stages of" exact="infection" post="to boost the innate immune response and promote viral"/>
  <result pre="of infection to boost the innate immune response and promote" exact="viral" post="clearance. IFN treatments are being tested in several clinical"/>
  <result pre="trials, but results are not available yet. However, as SARSâ€�CoVâ€�2" exact="infection" post="may also be accompanied by a dysregulated immune response"/>
  <result pre="oneâ€�third to oneâ€�fifth.91 3.2 Repositioned drugs that interfere with the" exact="viral" post="life cycle Several therapeutic molecules (Table 2), identified in"/>
  <result pre="of the renin/angiotensin pathway upregulates of ACE2 which can increase" exact="susceptibility to" post="SARSâ€�CoVâ€�2 infection.102 More recently, it has been shown that"/>
  <result pre="TABLE 2 Main repositioning molecules currently being tested against SARSâ€�CoVâ€�2" exact="infection" post="Compounds Target/MoA Tests in vitro (CoV) Clinical trials SARSâ€�CoVâ€�2"/>
  <result pre="(39) No data Vonoprazan PPI (39) No data Ivermectin Limits" exact="viral infection" post="(99) No data Oseltamivir Neuraminidase inhibitor No data No"/>
  <result pre="No data Vonoprazan PPI (39) No data Ivermectin Limits viral" exact="infection" post="(99) No data Oseltamivir Neuraminidase inhibitor No data No"/>
  <result pre="(in the nM to Î¼M range) the entry of vesicular" exact="stomatitis" post="virus pseudotypes carrying the SARSâ€�CoVâ€�2 S protein in different"/>
  <result pre="and nafamostat mesylate in VeroE6 cells infected by SARSâ€�CoVâ€�2 is" exact="lower" post="and probably not enough for a therapeutic utilization of"/>
  <result pre="membrane fusion, which is necessary for the release of the" exact="viral" post="genome into the cytoplasm of the host cell. Two"/>
  <result pre="proton pump inhibitors, such as omeprazole and vonoprazan, reduce the" exact="infection" post="of cells by SARSâ€�CoVâ€�2.39, 64 In addition, chloroquine and"/>
  <result pre="(HCQ), which have been extensively used for the treatment of" exact="malaria" post="with known safety and efficacy, also limit acidification of"/>
  <result pre="vesicles, and lysosomes.106 These molecules significantly reduce SARSâ€�CoV and SARSâ€�CoVâ€�2" exact="infection" post="inâ€‰vitro.48, 93, 94, 95, 106, 107 However, a recent"/>
  <result pre="study reported that HCQ does not have any effect on" exact="viral" post="load levels and does not protect macaques against SARSâ€�CoV"/>
  <result pre="Azithromycin is an antibiotic that has also antiviral activity in" exact="respiratory" post="viral infections.111 Interestingly, the MoA of azithromycin and HCQ"/>
  <result pre="is an antibiotic that has also antiviral activity in respiratory" exact="viral" post="infections.111 Interestingly, the MoA of azithromycin and HCQ may"/>
  <result pre="and prevent symptom worsening.114, 115, 116 Azithromycin may also inhibit" exact="viral" post="invasion by interfering with the CD147â€�mediated recognition mechanism.117 Nevertheless,"/>
  <result pre="reported that ivermectin inhibits SARSâ€�CoVâ€�2 with an ~5000â€�fold reduction in" exact="viral" post="RNA after 48â€‰hours.99 Ivermectin is a FDAâ€�approved antiparasitic molecule,"/>
  <result pre="study reported survival benefits during hospitalization,121 but no data on" exact="viral" post="load, highlighting the necessity to validate this observation in"/>
  <result pre="ivermectin, and highlights that the dose currently used for parasitic" exact="disease" post="do not effective against SARS infection.122 Finally, oseltamivir, a"/>
  <result pre="SARS infection.122 Finally, oseltamivir, a neuraminidase inhibitor that prevents influenza" exact="viral" post="particle release, is also investigated.123 Like for ritonavir/lopinavir, there"/>
  <result pre="Inserm through the REACTing initiative (REsearch and ACTion targeting emerging" exact="infectious" post="diseases), a multidisciplinary collaborative network of French research institutions"/>
  <result pre="multidisciplinary collaborative network of French research institutions working on emerging" exact="infectious diseases," post="which aims to prepare and respond to epidemics (B."/>
  <result pre="ErdmanD, GoldsmithCS, et al. A novel coronavirus associated with severe" exact="acute" post="respiratory syndrome. N Engl J Med. 2003;348(20):1953â€�1966.12690092 2ZakiAM, van"/>
  <result pre="GoldsmithCS, et al. A novel coronavirus associated with severe acute" exact="respiratory" post="syndrome. N Engl J Med. 2003;348(20):1953â€�1966.12690092 2ZakiAM, van BoheemenS,"/>
  <result pre="RAMF. Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. N Engl J Med. 2012;367(19):1814â€�1820.23075143 3WuF,"/>
  <result pre="ZhaoS, YuB, et al. A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature. 2020;579(7798):265â€�269.32015508 4ZhouF, YuT, DuR, et"/>
  <result pre="YuB, et al. A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature. 2020;579(7798):265â€�269.32015508 4ZhouF, YuT, DuR, et al."/>
  <result pre="et al. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVIDâ€�19 in Wuhan, China: a retrospective cohort"/>
  <result pre="NagataN, ShiratoK, KawaseM, TakedaM, TaguchiF. Efficient activation of the severe" exact="acute" post="respiratory syndrome coronavirus spike protein by the transmembrane protease"/>
  <result pre="ShiratoK, KawaseM, TakedaM, TaguchiF. Efficient activation of the severe acute" exact="respiratory" post="syndrome coronavirus spike protein by the transmembrane protease TMPRSS2."/>
  <result pre="KawaseM, TakedaM, TaguchiF. Efficient activation of the severe acute respiratory" exact="syndrome" post="coronavirus spike protein by the transmembrane protease TMPRSS2. J"/>
  <result pre="site in the spike protein of SARSâ€�CoVâ€�2 is essential for" exact="infection" post="of human lung cells. Mol Cell. 2020;78(4):779â€&quot;784. 32362314 12BelouzardS,"/>
  <result pre="for proteolytic activation and spread of SARSâ€�CoVâ€�2 in human airway" exact="epithelial" post="cells and provide promising drug targets. bioRxiv;2020.04.15.042085. https://www.biorxiv.org/content/10.1101/2020.04.15.042085v1.abstract. [Accessed"/>
  <result pre="trials for COVIDâ€�19. Lancet Digit Heal. 2020;2:286â€&quot;287. 16Clinical Management of" exact="Severe" post="Acute Respiratory Infection When COVIDâ€�19 Is Suspected. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed"/>
  <result pre="for COVIDâ€�19. Lancet Digit Heal. 2020;2:286â€&quot;287. 16Clinical Management of Severe" exact="Acute" post="Respiratory Infection When COVIDâ€�19 Is Suspected. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed May"/>
  <result pre="COVIDâ€�19. Lancet Digit Heal. 2020;2:286â€&quot;287. 16Clinical Management of Severe Acute" exact="Respiratory" post="Infection When COVIDâ€�19 Is Suspected. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed May 27,"/>
  <result pre="Lancet Digit Heal. 2020;2:286â€&quot;287. 16Clinical Management of Severe Acute Respiratory" exact="Infection" post="When COVIDâ€�19 Is Suspected. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed May 27, 2020."/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory metaâ€�analysis."/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory metaâ€�analysis. J Infect"/>
  <result pre="SiuLK, et al. Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospital."/>
  <result pre="et al. Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospital. J"/>
  <result pre="al. Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospital. J Antimicrob"/>
  <result pre="monoclonal antibodies targeting multiple antigenic sites on the Middle East" exact="respiratory" post="syndrome coronavirus spike glycoprotein to avoid neutralization escape. J"/>
  <result pre="antibodies targeting multiple antigenic sites on the Middle East respiratory" exact="syndrome" post="coronavirus spike glycoprotein to avoid neutralization escape. J Virol."/>
  <result pre="2018;92(10):2002â€&quot;2017. 27HofmannH, HattermannK, MarziA, et al. S protein of severe" exact="acute" post="respiratory syndromeâ€�associated coronavirus mediates entry into hepatoma cell lines"/>
  <result pre="27HofmannH, HattermannK, MarziA, et al. S protein of severe acute" exact="respiratory" post="syndromeâ€�associated coronavirus mediates entry into hepatoma cell lines and"/>
  <result pre="2004;78(12):6134â€�6142.15163706 28HeY, LuH, SiddiquiP, ZhouY, JiangS. Receptorâ€�binding domain of severe" exact="acute" post="respiratory syndrome coronavirus spike protein contains multiple conformationâ€�dependent epitopes"/>
  <result pre="28HeY, LuH, SiddiquiP, ZhouY, JiangS. Receptorâ€�binding domain of severe acute" exact="respiratory" post="syndrome coronavirus spike protein contains multiple conformationâ€�dependent epitopes that"/>
  <result pre="LuH, SiddiquiP, ZhouY, JiangS. Receptorâ€�binding domain of severe acute respiratory" exact="syndrome" post="coronavirus spike protein contains multiple conformationâ€�dependent epitopes that induce"/>
  <result pre="2005;174(8):4908â€�4915.15814718 29SuiJ, LiW, MurakamiA, et al. Potent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human mAb to"/>
  <result pre="29SuiJ, LiW, MurakamiA, et al. Potent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human mAb to S1"/>
  <result pre="LiW, MurakamiA, et al. Potent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
  <result pre="BabcockGJ, RobertsA, et al. Development and characterization of a severe" exact="acute" post="respiratory syndromeâ€&quot;associated coronavirusâ€&quot;neutralizing human monoclonal antibody that provides effective"/>
  <result pre="RobertsA, et al. Development and characterization of a severe acute" exact="respiratory" post="syndromeâ€&quot;associated coronavirusâ€&quot;neutralizing human monoclonal antibody that provides effective immunoprophylaxis"/>
  <result pre="J Infect Dis. 2005;191(4):507â€�514.15655773 31WrappD, De VliegerD, CorbettKS, et al." exact="Structural" post="basis for potent neutralization of betacoronaviruses by singleâ€�domain camelid"/>
  <result pre="2020;181:281â€&quot;292. 32155444 34MonteilV, KwonH, PradoP, et al. Inhibition of SARSâ€�CoVâ€�2" exact="infections" post="in engineered human tissues using clinicalâ€�grade soluble human ACE2."/>
  <result pre="The discovery of angiotensinâ€�converting enzyme 2 and its role in" exact="acute" post="lung injury in mice. Exp Physiol. 2008;93:543â€�548.18448662 36WangK, ChenW,"/>
  <result pre="LenevaIA, PÃ©cheurEâ€�I, PolyakSJ. Arbidol: a broadâ€�spectrum antiviral compound that blocks" exact="viral" post="fusion. Curr Med Chem. 2008;15(10):997â€�1005.18393857 39TouretF, GillesM, BarralK, et"/>
  <result pre="of arbidol and its derivatives against the pathogen of severe" exact="acute" post="respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9â€�13."/>
  <result pre="arbidol and its derivatives against the pathogen of severe acute" exact="respiratory" post="syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9â€�13. 41DengL,"/>
  <result pre="and its derivatives against the pathogen of severe acute respiratory" exact="syndrome" post="in the cell cultures. Vopr Virusol. 2008;53(4):9â€�13. 41DengL, LiC,"/>
  <result pre="al. Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: a retrospective cohort study. J Infect. 2020;81:1â€&quot;5. 32315723"/>
  <result pre="Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: a retrospective cohort study. J Infect. 2020;81:1â€&quot;5. 32315723"/>
  <result pre="rhesus monkeys. Nature. 2016;531(7594):381â€�385.26934220 46AgostiniML, AndresEL, SimsAC, et al. Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GSâ€�5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GSâ€�5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221â€&quot;18. 29511076 47de"/>
  <result pre="An orally bioavailable broadâ€�spectrum antiviral inhibits SARSâ€�CoVâ€�2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in mice. Sci Transl"/>
  <result pre="a directâ€�acting antiviral that inhibits RNAâ€�dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potency. J Biol"/>
  <result pre="directâ€�acting antiviral that inhibits RNAâ€�dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potency. J Biol Chem."/>
  <result pre="antiviral that inhibits RNAâ€�dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potency. J Biol Chem. 2020;295:6785â€&quot;6797."/>
  <result pre="2004;59(3):252â€�256.14985565 57BhatnagarT, MurhekarMV, SonejaM, et al. Lopinavir/ritonavir combination therapy amongst" exact="symptomatic" post="coronavirus disease 2019 patients in India: protocol for restricted"/>
  <result pre="MurhekarMV, SonejaM, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus" exact="disease" post="2019 patients in India: protocol for restricted public health"/>
  <result pre="of the index patient who caused tertiary transmission of COVIDâ€�19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
  <result pre="the application of lopinavir/ritonavir for the treatment of COVIDâ€�19 infected" exact="pneumonia" post="monitored by quantitative RTâ€�PCR. J Korean Med Sci. 2020;35(6):e79.32056407"/>
  <result pre="FDAâ€�approved compound library identifies four smallâ€�molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother."/>
  <result pre="compound library identifies four smallâ€�molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875â€�4884.24841269"/>
  <result pre="of SARSâ€�associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719â€�725.15144898 62KadamRU, WilsonIA." exact="Structural" post="basis of influenza virus fusion inhibition by the antiviral"/>
  <result pre="U S A. 2017;114(2):206â€�214.28003465 63VigantF, SantosNC, LeeB. Broadâ€�spectrum antivirals against" exact="viral" post="fusion. Nat Rev Microbiol. 2015;13(7):426â€�437.26075364 64RivaL, YuanS, YinX, et"/>
  <result pre="Mechanism of action of interferon and ribavirin in treatment of" exact="hepatitis C." post="Nature. 2005;436(7053):967â€�972.16107837 68FerronF, SubissiL, Silveira De MoraisAT, et al."/>
  <result pre="C. Nature. 2005;436(7053):967â€�972.16107837 68FerronF, SubissiL, Silveira De MoraisAT, et al." exact="Structural" post="and molecular basis of mismatch correction and ribavirin excision"/>
  <result pre="potential therapeutics. PLoS Pathog. 2013;9(8):e1003565.23966862 70StrÃ¶herU, DiCaroA, LiY, et al." exact="Severe" post="acute respiratory syndromeâ€&quot;related coronavirus is inhibited by interferonâ€�Î±. J"/>
  <result pre="therapeutics. PLoS Pathog. 2013;9(8):e1003565.23966862 70StrÃ¶herU, DiCaroA, LiY, et al. Severe" exact="acute" post="respiratory syndromeâ€&quot;related coronavirus is inhibited by interferonâ€�Î±. J Infect"/>
  <result pre="PLoS Pathog. 2013;9(8):e1003565.23966862 70StrÃ¶herU, DiCaroA, LiY, et al. Severe acute" exact="respiratory" post="syndromeâ€&quot;related coronavirus is inhibited by interferonâ€�Î±. J Infect Dis."/>
  <result pre="KumarM, ShinOS. Favipiravir and ribavirin inhibit replication of Asian and" exact="African" post="strains of Zika virus in different cell models. Viruses."/>
  <result pre="models. Viruses. 2018;10(2):72. 75ZmurkoJ, MarquesRE, ScholsD, VerbekenE, SJFK, NeytsJ. The" exact="viral" post="polymerase inhibitor 7â€�deazaâ€�2â€™â€�Câ€�methyladenosine is a potent inhibitor of in"/>
  <result pre="potent inhibitor of in vitro Zika virus replication and delays" exact="disease" post="progression in a robust mouse infection model. PLoS Negl"/>
  <result pre="virus replication and delays disease progression in a robust mouse" exact="infection" post="model. PLoS Negl Trop Dis. 2016;10(5):e0004695.27163257 76DelangL, Segura GuerreroN,"/>
  <result pre="2016;10(5):e0004695.27163257 76DelangL, Segura GuerreroN, TasA, et al. Mutations in the" exact="chikungunya" post="virus nonâ€�structural proteins cause resistance to favipiravir (Tâ€�705), a"/>
  <result pre="LÃ¼dtkeA, WurrS, RiegerT, MuÃ±ozâ€�FontelaC, GÃ¼ntherS. Successful treatment of advanced Ebola" exact="virus infection" post="with Tâ€�705 (favipiravir) in a small animal model. Antiviral"/>
  <result pre="WurrS, RiegerT, MuÃ±ozâ€�FontelaC, GÃ¼ntherS. Successful treatment of advanced Ebola virus" exact="infection" post="with Tâ€�705 (favipiravir) in a small animal model. Antiviral"/>
  <result pre="LeverMS. Postâ€�exposure efficacy of oral Tâ€�705 (favipiravir) against inhalational Ebola" exact="virus infection" post="in a mouse model. Antiviral Res. 2014;104:153â€�155.24462697 81collab: Shannon"/>
  <result pre="Postâ€�exposure efficacy of oral Tâ€�705 (favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse model. Antiviral Res. 2014;104:153â€�155.24462697 81collab: Shannon"/>
  <result pre="TRIF contributes to a protective innate immune response to severe" exact="acute" post="respiratory syndrome coronavirus infection. MBio. 2015;6(3):e00638â€�15.26015500 87ZieglerCGK, AllonSJ, NyquistSK,"/>
  <result pre="contributes to a protective innate immune response to severe acute" exact="respiratory" post="syndrome coronavirus infection. MBio. 2015;6(3):e00638â€�15.26015500 87ZieglerCGK, AllonSJ, NyquistSK, et"/>
  <result pre="to a protective innate immune response to severe acute respiratory" exact="syndrome" post="coronavirus infection. MBio. 2015;6(3):e00638â€�15.26015500 87ZieglerCGK, AllonSJ, NyquistSK, et al."/>
  <result pre="SARSâ€�CoVâ€�2 receptor ACE2 is an interferonâ€�stimulated gene in human airway" exact="epithelial" post="cells and is detected in specific cell subsets across"/>
  <result pre="2020;181:1016â€&quot;1035. 32413319 88ZhangC, WuZ, LiJâ€�W, ZhaoH, WangGQ. The cytokine release" exact="syndrome" post="(CRS) of severe COVIDâ€�19 and Interleukinâ€�6 receptor (ILâ€�6R) antagonist"/>
  <result pre="How to reduce the likelihood of coronavirusâ€�19 (CoVâ€�19 or SARSâ€�CoVâ€�2)" exact="infection" post="and lung inflammation mediated by ILâ€�1. J Biol Regul"/>
  <result pre="reduce the likelihood of coronavirusâ€�19 (CoVâ€�19 or SARSâ€�CoVâ€�2) infection and" exact="lung inflammation" post="mediated by ILâ€�1. J Biol Regul Homeost Agents. 2020;34(2):11â€&quot;16."/>
  <result pre="et al. Induction of proâ€�inflammatory cytokines (ILâ€�1 and ILâ€�6) and" exact="lung inflammation" post="by Coronavirusâ€�19 (COVIâ€�19 or SARSâ€�CoVâ€�2): antiâ€�inflammatory strategies. J Biol"/>
  <result pre="et al. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. 2005;2(1):69.16115318 94KeyaertsE, VijgenL, MaesP, NeytsJ,"/>
  <result pre="VijgenL, MaesP, NeytsJ, Van RanstM. In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun."/>
  <result pre="MaesP, NeytsJ, Van RanstM. In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264â€�268.15351731"/>
  <result pre="NeytsJ, Van RanstM. In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264â€�268.15351731 95YaoX,"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis. 2020."/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis. 2020. [Online"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARSâ€�CoVâ€�2). Clin Infect Dis. 2020. [Online ahead"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARSâ€�CoVâ€�2" exact="infection" post="in vitro. Cell Discov. 2020;6(1):16.32194981 97GaoJ, TianZ, YangX. Breakthrough:"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVIDâ€�19 associated" exact="pneumonia" post="in clinical studies. Biosci Trends. 2020;14(1):72â€�73.32074550 98GautretP, LagierJâ€�C, ParolaP,"/>
  <result pre="of the reninâ€&quot;angiotensin system be withdrawn in patients with COVIDâ€�19?Eur" exact="Heart" post="J. 2020;41:1801â€&quot;1803. 32196087 101MengJ, XiaoG, ZhangJ, et al. Reninâ€�angiotensin"/>
  <result pre="Infect. 2020;9(1):757â€�760.32228222 102SukumaranV, TsuchimochiH, TatsumiE, ShiraiM, PearsonJT. Azilsartan ameliorates diabetic" exact="cardiomyopathy" post="in young db/db mice through the modulation of ACEâ€�2/ANG"/>
  <result pre="32142651 106SavarinoA, BoelaertJR, CassoneA, MajoriG, CaudaR. Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases. Lancet Infect"/>
  <result pre="2020. 111GielenV, JohnstonSL, EdwardsMR. Azithromycin induces antiâ€�viral responses in bronchial" exact="epithelial" post="cells. Eur Respir J. 2010;36(3):646â€�654.20150207 112DereticV, TimminsGS. Azithromycin and"/>
  <result pre="112DereticV, TimminsGS. Azithromycin and ciprofloxacin have a chloroquineâ€�like effect on" exact="respiratory" post="epithelial cells. bioRxiv. 2020. https://www.biorxiv.org/content/10.1101/2020.03.29.008631v1. Accessed April 5, 2020."/>
  <result pre="TimminsGS. Azithromycin and ciprofloxacin have a chloroquineâ€�like effect on respiratory" exact="epithelial" post="cells. bioRxiv. 2020. https://www.biorxiv.org/content/10.1101/2020.03.29.008631v1. Accessed April 5, 2020. 113PaniA,"/>
  <result pre="Accessed April 5, 2020. 113PaniA, LauriolaM, RomandiniA, ScaglioneF. Macrolides and" exact="viral" post="infections: focus on azithromycin in COVIDâ€�19 pathology. Int J"/>
  <result pre="but not fibrinogen production in hepatocytes infected with cytomegalovirus and" exact="chlamydia" post="pneumoniae. J Lab Clin Med. 2004;144(1):18â€�26.15252403 117UlrichH, PillatMM. CD147"/>
  <result pre="alter capsid protein distribution in mammalian cells and reduce Venezuelan" exact="Equine" post="Encephalitis Virus replication. Antiviral Res. 2013;100(3):662â€�672.24161512 120TayMYF, FraserJE, ChanWKK,"/>
  <result pre="capsid protein distribution in mammalian cells and reduce Venezuelan Equine" exact="Encephalitis" post="Virus replication. Antiviral Res. 2013;100(3):662â€�672.24161512 120TayMYF, FraserJE, ChanWKK, et"/>
 </snippets>
</snippetsTree>
